Pleno Inc. has officially launched its RAPTOR™ instrument platform with a new commercial agreement, its first, with Slopes Bio, Inc., a high-complexity accredited laboratory. This partnership comes after a successful pilot project where the companies processed over 400 patient samples and developed a polygenic risk score panel, demonstrating the superior accuracy, target plexity, and economic benefits of Pleno's proprietary Hypercoding™ technology. This technology, which can detect up to 10,000 targets per sample, is designed to revolutionize biological target detection by simplifying complex multi-omic workflows.

Under the terms of the agreement, Slopes Bio will purchase up to five RAPTOR instruments and the necessary consumables to process more than 100,000 samples annually. The initial two instruments are scheduled for deployment in Slopes' Utah-based production lab starting in early September 2025. According to Pleno CEO Dr. Vik Vaz, this collaboration validates the commercial viability and real-world scalability of the platform. The partnership also extends beyond the initial deployment, with plans to jointly develop new high-sample-volume applications in personalized health and wellness testing. This strategic collaboration between Pleno and Slopes Bio is positioned to capitalize on the growing demand for high-throughput biological analysis, promising to deliver significant performance and cost improvements across a wide range of applications, including oncology and pharmacogenomics.